Ergothioneine: the science in depth

By Brian · 43 min read · Updated September 14, 2026

Three key takeaways

• OCTN1 brings EGT into cells. Cells with the transporter accumulate and retain EGT. ^[1]
• Mitochondrial entry is observed; its route is unresolved. Uptake persisted in mitochondrial preparations from OCTN1-knockout mice. ^[2]
• EGT reacts differently with different oxidants. Laboratory assays show hydroxyl-radical and hypochlorous-acid scavenging, but no rapid direct reaction with superoxide or hydrogen peroxide. ^[3]

This is the deep dive. If you have not read the overview yet, start with Ergothioneine (EGT) for rats: could it be their “taurine”?, which lays out the big idea in plain terms. This page is for readers who want to go further into the weeds: how ergothioneine actually gets into a cell, the two separate ways it protects that cell, what it does organ by organ, and exactly where the science is solid versus where it is still an open question. Nothing here is a prescription, and none of it replaces a vet. It is the real machinery behind the story, written as honestly as we can put it.

A note on how to read it. We label claims as we go. Established means it is well supported, often in several studies or confirmed by gene-knockout experiments. Mechanistic means the chemistry or biology makes sense and there is some evidence, but it is not nailed down. Open hypothesis means it is a reasonable idea built on published facts that nobody has actually tested yet, and we are raising it on purpose so that someone will. Most of what follows is in animals or cells; we say so when a result is only correlational in people.

1. The one doorway: OCTN1 (SLC22A4)

Everything about ergothioneine starts with one fact: a cell cannot let it in by itself. The molecule carries a fixed positive charge, so it does not drift across the oily cell membrane the way many small molecules do. To get inside, it has to be carried, and it is carried by a single dedicated protein. That protein is OCTN1, the product of the gene SLC22A4. It was identified as the ergothioneine transporter in 2005, which is why it also goes by the name ETT, the ergothioneine transporter.^[1] It is high-affinity and selective: it grabs ergothioneine tightly even when there is very little around, with a half-saturating concentration (the Km) in the low tens of micromolar.^[1] (established)

How important is that one doorway? Breed a mouse that lacks the gene for it and the animal ends up with almost no ergothioneine anywhere in its body, even when there is plenty in the food.^[4] No transporter, no ergothioneine, full stop. This is the single most important thing to understand about the molecule: its entire biology is downstream of this one gate. A tissue that builds a lot of OCTN1 fills up with ergothioneine; a tissue that builds none gets none, no matter how much the animal eats. (established)

So where is the gate built? OCTN1 is concentrated in a predictable set of places: the kidney’s proximal tubule (very high), the developing red blood cells of the bone marrow, monocytes and other immune cells, the liver, the lining of the gut, the brain, the lens of the eye, and oxidative (“slow-twitch”) skeletal muscle and heart.^[5] That list reads like a map of the tissues that take the most oxidative punishment, which is part of why ergothioneine is interesting. Rats are not an afterthought here: the rat version of the transporter has been shown to carry ergothioneine in its own right, so this is genuinely rat biology and not a human story we are hoping applies.^[6] (established)

Two finer points worth knowing. First, the doorway is not identical in every individual. In people there is a common variant of the gene called L503F that shifts how the transporter behaves, changing how it handles some drug substrates, though ergothioneine transport itself looks similar across the common variants.^[7] And because your body cannot make ergothioneine, all of it comes from your diet, so what matters is how much you take in and hold onto. Large human studies find that this is partly genetic: a person’s baseline blood ergothioneine level tracks with inherited differences at the transporter gene, so two people on the same diet can settle at different levels.^[8] That idea comes back below when we get to the blonde-rat hypothesis. Second, once OCTN1 loads ergothioneine into a tissue, the body is remarkably reluctant to let it go. Inside cells the concentration runs into the millimolar range, far higher than the micromolar trace in blood, and when people are given a measured dose almost none of it comes back out in the urine; the body reabsorbs and keeps it for weeks.^[9] A body does not build a dedicated transporter and then hoard the cargo for weeks unless that cargo is worth keeping. (established)

There is one more twist that matters for sick animals, and the game leans on it. When a tissue is stressed or damaged, especially the kidney, it builds more OCTN1, as if calling for help. We come back to the cruel irony of that below: the diseases that most need ergothioneine are often the same ones that leave the body short of it.

2. A family of antioxidants through the same doorway

Here is something most write-ups skip. OCTN1 is not reserved for ergothioneine alone. It carries a small family of diet-derived molecules, several of them antioxidants or close chemical relatives, and that fact opens up two ideas that run through the rest of this page: a competition problem and a compensation possibility.

• Ergothioneine itself, from mushrooms and soil microbes, the main character.
• Stachydrine (also called proline betaine), found in citrus and in alfalfa, which the very paper that discovered the transporter showed it carries alongside ergothioneine.^[1]
• Hercynine, which is the immediate biochemical precursor of ergothioneine (the microbe makes hercynine first, then adds the sulfur), and turns up in some of the same foods.
• Selenoneine, the selenium twin of ergothioneine: the same ring with a selenium atom where ergothioneine has sulfur. It is the main form of organic selenium in the blood of tuna, with mackerel close behind and other fish carrying far less, and it is a powerful radical scavenger in its own right, hundreds of times more effective than ergothioneine in the same test.^[10]
• L-carnitine, the energy-shuttle molecule. This one is not an antioxidant, and it is only a low-affinity passenger of OCTN1 (its main transporter is the sibling OCTN2), but it gets a mention because OCTN1’s full name is the carnitine/organic cation transporter.^[4] Hold that thought, lightly, for the competition hypothesis below.

So the picture is not “one molecule, one transporter.” It is one transporter serving a handful of diet-derived compounds, most of which a wild rat would forage and a captive rat largely would not. That shared doorway is what makes the competition and compensation questions in section 5 worth raising at all.

3. How ergothioneine actually works (two separate jobs)

Ergothioneine does two quite different things inside a cell. One is the classic antioxidant shield it was known for from the start. The other is a signaling role only worked out in 2025, and it is the one that explains the lifespan and muscle results. They are worth keeping separate in your head, because they have different evidence behind them.

Job one: the shield that does not turn on you

Most antioxidants work by sacrificing themselves: they hand off an electron to neutralize a radical and, in doing so, become a mild radical themselves, which then has to be cleaned up by something else. Vitamin C and glutathione both do this. Ergothioneine is built differently. At the pH inside a living cell it sits almost entirely in a stable form called the thione (a carbon double-bonded to sulfur), rather than the reactive thiol form. That stability is the whole point: ergothioneine can quench the body’s single most dangerous radical, the hydroxyl radical, almost instantly, and it can mop up singlet oxygen, peroxynitrite, and hypochlorous acid, without itself becoming a troublemaker afterward.^[5] (established for the chemistry)

It has a second trick in the same job. The hydroxyl radical is usually made on the spot by loose iron or copper reacting with hydrogen peroxide, the so-called Fenton reaction. Ergothioneine binds those loose metal ions and locks them up, so the dangerous radical is never made in the first place.^[5] Preventing the fire is better than putting it out, and this is especially relevant in the kidney, where iron-driven damage is a real problem. (established)

Beyond directly scavenging, ergothioneine turns up the cell’s own antioxidant systems rather than replacing them, and this is the better-supported half of the story. It activates the Nrf2 pathway, the master switch that turns on a battery of protective genes, and this has been measured with ergothioneine as the input in several settings. In human skin cells it drove Nrf2 into the nucleus and raised GCLC, the rate-limiting enzyme that builds glutathione, alongside heme oxygenase-1 and NQO1, and total glutathione went up.^[11][12] In human blood-vessel (endothelial) cells it was taken up and protected them from oxidative stress.^[13] And in rats it switched on Nrf2 and protected the kidney in both a cisplatin-injury model and a diabetic-kidney model.^[14][15] So the headline is concrete: ergothioneine tells the cell to build and keep more glutathione, its main thiol antioxidant. (Established that EGT activates Nrf2 and raises glutathione, across human cells and rat kidney.)

One popular shorthand needs correcting, because it sounds right and is probably wrong. You will often read that ergothioneine boosts NADPH (the cell’s reducing fuel) by ramping up the pentose-phosphate pathway through an enzyme called G6PD, and that this is how it recharges glutathione. In fact no study has measured G6PD, NADPH, or pentose-phosphate flux after ergothioneine in any mammal, and there is good reason to doubt the cell needs to make more G6PD at all. G6PD is not throttled by how much of it the cell builds, it is throttled by demand: NADPH itself puts a brake on G6PD, so when NADPH gets used up the brake comes off and flux through the existing enzyme rises on its own. Ergothioneine raises that demand from two directions, since recycling a bigger glutathione pool costs NADPH, and ergothioneine’s own spent form is regenerated by an NADPH-using enzyme, thioredoxin reductase.^[16] So if ergothioneine does increase pentose-pathway flux, the likely route is pulling harder on the G6PD already there, not making more of it, and either way it has not been measured. We flag this whole step as an open question, not a fact. The honest summary: ergothioneine is a fast direct scavenger, and on top of that a switch that tells the cell to build and recycle more of its own glutathione. One caveat on all of the cell-level work above: it was done in isolated cells under heavy oxidative stress, so it shows the direction of the effect, not that the same thing happens at a dietary dose in a living rat.

One honest caveat sits over all of Job one. Ergothioneine behaves like a held-in-reserve antioxidant rather than a first responder: when healthy young people were given it, their oxidative-damage markers, already low, did not fall any further,^[9] and mice bred without the OCTN1 doorway look perfectly normal until something stresses them.^[4] That fits how we frame it throughout, insurance rather than a drug. A rat already eating well may show no measurable change; the case for ergothioneine is what it can do when a tissue is under load, not a promise that more is always better.^[17]

Job two: the 2025 signaling cascade that regenerates NAD+

This is the new and genuinely surprising part, and it is the mechanism behind the headline lifespan and muscle results. In 2025 a team showed that ergothioneine is not just a shield; it is a trigger. The chain runs like this:^[19]

1. Ergothioneine acts as an alternative substrate for an enzyme called CSE (cystathionine gamma-lyase).
2. CSE turns it into a small, controlled burst of hydrogen sulfide (H₂S), which is a real signaling gas in the body, not just a waste product.
3. That H₂S adds a sulfur tag to reactive spots on more than three hundred proteins, a reversible mark called persulfidation that both protects those spots from permanent oxidation and switches some enzymes on.
4. One of the enzymes it switches on is cytosolic glycerol-3-phosphate dehydrogenase (cGPDH), which in turn regenerates NAD⁺, the central energy-and-repair currency of the cell that quietly drains away with age.

The reason this is taken seriously rather than treated as a just-so story is the knockout test. Remove CSE, and ergothioneine’s benefit vanishes. Remove cGPDH, and it vanishes too.^[19] When deleting a specific gene abolishes an effect, you have found a real mechanism, not a coincidence. (established for this cascade, in worms and aged rats)

One distinction is worth making because it gets muddled in supplement marketing. Ergothioneine is not an NAD⁺ “raw material” the way NMN, NR, or trigonelline are. Those are building blocks the cell can assemble into NAD⁺. Ergothioneine is upstream of that: it is a signal that tells the cell to turn its NAD⁺-regenerating machinery back on. That is a different kind of intervention, and it is why ergothioneine behaves differently from the NAD⁺ precursors people are more familiar with.

Notice that job two has a hard requirement built into it. If a cell has lost its CSE enzyme, firing ergothioneine at it does nothing for NAD⁺. And the cells most likely to be short on CSE are old, damaged ones, exactly the cells you would most want to rescue. This is not a flaw we are glossing over; it is a real limit of the molecule, and we treat it as one.

4. What it does, organ by organ

Kidney: the flagship, and a cruel paradox

The kidney is the reason most geriatric-rat keepers should care, and it is where the OCTN1 story is densest. Ergothioneine concentrates in the proximal tubule, the segment that does the heavy reabsorption work and is most exposed to oxidative and iron-driven injury. In rodents, ergothioneine protects that tissue and slows the slide from an acute kidney injury into permanent chronic kidney disease.^[20] Given that age-related kidney decline is one of the most common ways pet rats fail, a molecule that defends exactly this segment is worth a hard look. (established in rodents)

Now the paradox, and it is a real one. Chronic kidney disease itself lowers the body’s ergothioneine. It does this not at the kidney but at the gut: kidney disease disrupts the intestinal OCTN1 that absorbs ergothioneine from food, so a sick animal pulls less in from its diet.^[21] At the same time, the damaged kidney builds more OCTN1, trying to recruit more ergothioneine to the injured tissue. So the organ is asking louder for help precisely as the disease is cutting off the supply. That is the kind of vicious circle where keeping the diet rich in ergothioneine, before there is a problem, is the cheap and sensible move. (established for the CKD-lowers-EGT link)

Aged muscle: the endurance and stem-cell result

The 2025 study did its functional work in aged rats, which is about as relevant a model as a rat keeper could ask for. Old rats given ergothioneine showed higher NAD⁺ in muscle, roughly doubled treadmill endurance, more muscle mass, and denser blood-vessel networks feeding the muscle. It also raised the number of PAX7-positive satellite cells, the dormant stem cells that repair muscle.^[19] All of this runs through job two, the CSE to H₂S to cGPDH to NAD⁺ cascade described above; it is the same mechanism showing up as a whole-animal effect. (established in aged rats, short-term healthspan)

Brain: real but off-label

Ergothioneine crosses into the brain. When mice eat it, it shows up in brain tissue, and in those studies it had a measurable antidepressant-like effect.^[22] In cultured neurons it lowers the abnormal tau phosphorylation linked to Alzheimer-type damage by inactivating an enzyme called GSK-3 beta.^[23] We flag the brain story clearly: the distribution-to-brain part is solid in mice, but the neurodegeneration angle is mostly cell-culture work, and we are not claiming ergothioneine treats any brain disease in a rat. It is included because the same OCTN1 doorway is the reason ergothioneine reaches the brain at all, which ties the whole picture together. (mechanistic to established for brain uptake; in-vitro for the tau effect)

Lungs and airways

Ergothioneine concentrates in lung tissue, and the studies that exist point the same way. In rats given an inflammatory challenge to the lungs, it reduced the acute injury and inflammation;^[24] in cell and animal models of cigarette-smoke damage it protected the alveolar cells that line the air sacs and limited the scarring response, and the damage was worse in mice bred to lack the OCTN1 doorway that lets ergothioneine in.^[17] None of this studied Mycoplasma, the infection most pet rats carry, so it is not evidence that ergothioneine treats a sick rat’s lungs. But chronic respiratory disease is what takes most pet rats in the end, and a nutrient the lung holds onto and uses to defend that lining is worth knowing about. (rat injury and smoke models; not tested against mycoplasma)

Reproduction: a gamete protector, not a fertility drug

The body concentrates ergothioneine in the reproductive tract through OCTN1, and it has been a known part of boar seminal plasma since the 1950s.^[25][17] It behaves as a gamete protector: in the lab it improves the maturation of pig eggs in a dish, which is the only species this was shown in, and there are separate reports on the motility and survival of stored sperm,^[26][27] and in rats it shielded the testis from oxidative injury in a varicocele model.^[28] OCTN1 also sits on the rat placenta, so some of what a mother takes in reaches her young,^[29] and a one-generation reproduction study found it safe through pregnancy with no developmental harm.^[30] That same study is the honest catch, though: in healthy rats ergothioneine produced no change in fertility. So the fair read is that it protects sperm and eggs from oxidative damage and is safe across breeding, but there is no evidence it raises fertility in a healthy animal. The separate, behavioral side of male fertility in a tame line is one of our open research questions. (lab and injury-model protection established; no healthy-animal fertility benefit)

5. Three open hypotheses we are putting on the table

These are not findings. They are reasonable ideas built entirely on published facts that, as far as we can tell, nobody has tested. We are raising them on purpose. We would rather put a good question into the open and have it proven or disproven than sit on it.

Hypothesis one: are blonde (Rab38) rats especially short on ergothioneine?

Three published facts line up suggestively. The blonde or dilute coat in rats traces to the gene Rab38.^[31] In our colony this Rab38 deletion was independently characterized and presented by Kido and Kuramoto (Tokyo University of Agriculture, 2024).^[32] Rab38 is a small GTPase whose job is to traffic membrane proteins to their proper destinations inside the cell. Losing it also causes protein to leak into the urine, and the mechanism is impaired reabsorption in the kidney’s proximal tubule, not a leaky filter.^[33] That reabsorption is the work of two surface receptors, megalin and cubilin, which pull filtered protein back into the tubule cells,^[34] and they are exactly the kind of apical (surface) membrane cargo that a trafficking gene like Rab38 helps deliver into place. The ergothioneine transporter OCTN1 is another surface protein working in that same tubule. The untested bridge: if Rab38 is part of the machinery that delivers OCTN1 to the cell surface, then a Rab38-deficient blonde rat might place too little OCTN1 where it belongs, take up less ergothioneine, and end up especially deficient and especially dependent on getting it from the diet. That would tie together two things already documented in Rab38-mutant rats: lighter coats and vulnerable kidneys. Whether OCTN1 is actually Rab38 cargo is the open experiment. The overview page lays this out in full, with the exact test we are asking a lab to run. (open hypothesis on published scaffolding)

Hypothesis two: do common drugs and supplements crowd ergothioneine out of its doorway?

Ergothioneine has only the one doorway, OCTN1, so it is worth asking what else uses it. Metformin, the world’s most prescribed diabetes drug, interacts with OCTN1; it has been shown to inhibit transport through it.^[35] Metformin is taken at very high daily doses, on the order of one to two grams, and it is cleared by the kidney, so it reaches high concentrations right where OCTN1 sits in the renal tubule. If it ties up that doorway, the hundreds of millions of people on metformin could be quietly short of ergothioneine in the very organ most likely to decline with age. We have to be fair about the uncertainty: the transporter’s own discoverers have argued it is highly selective for ergothioneine and is not really a general drug transporter, so whether metformin is meaningfully carried by it or merely blocks it is genuinely unsettled.^[36] Either way, competition for one doorway is plausible, and that is exactly the kind of unanswered question worth flagging.

The same logic applies, but far more weakly, to L-carnitine. Carnitine is mainly carried by the sibling transporter OCTN2; it is only a low-affinity passenger of OCTN1,^[4] so any competition with ergothioneine would only plausibly bite under heavy, long-term carnitine supplementation, the kind a human bodybuilder might take, and is unlikely to matter for a pet rat. We mention it for completeness, not as a real worry. (One honest correction: an earlier version of this idea named creatine. Creatine uses a different transporter again and has no published OCTN1 link, so even the weak carnitine version is the one that stands.) The metformin question is the one actually worth testing: measure blood ergothioneine in long-term metformin users against matched controls. It matters for a great many people, and someone should look. (open hypothesis; the metformin-OCTN1 interaction is published, the deficiency consequence is not)

Hypothesis three: can a wild diet compensate for scarce ergothioneine with its relatives?

Recall from section 2 that OCTN1 carries a small family of diet-derived antioxidants, not ergothioneine alone. That raises a question we find genuinely interesting. If a rat’s ergothioneine supply runs short, might it partly compensate by eating the relatives, stachydrine from citrus and alfalfa, selenoneine from fish, hercynine from the same fungal sources? The analogy is the way a tea of pine needles once warded off scurvy as an unexpected source of vitamin C. We do not know how much these molecules truly overlap with ergothioneine in function, or whether that overlap would be enough to prevent the extra illness and earlier death that real deficiency would cause. It is a real, testable question. In the meantime it argues for the same practical thing the rest of this page does: a varied, whole-foods diet rather than betting everything on a single compound. (open hypothesis)

6. Honest limits: where this is strong and where it is thin

We would rather undersell this than oversell it, so here is the candid accounting.

• The human longevity link is correlation, not proof. In a large cohort, higher blood ergothioneine tracked with lower mortality and less cardiovascular disease.^[37] But ergothioneine turned out to be the single metabolite most tied to a health-conscious diet, so the people with high levels also did a hundred other healthy things. Read it as a strong hint to investigate, not as evidence that ergothioneine extends human life.
• The mammalian lifespan data are real but limited to mice. A low daily dose, about four to five milligrams per kilogram, raised median lifespan roughly sixteen percent in male mice.^[38] That is the first hard mammalian lifespan result. The rat work is shorter-term healthspan, not lifespan, and worms are worms. So “extends lifespan in a mammal” is true and important, and also rests on one species so far.
• The effective rodent doses are experimental. The aged-rat muscle work used about twenty milligrams per kilogram per day, and older kidney-protection work used up to seventy. A conservative dietary-equivalent, scaled from human intake, is closer to one to three milligrams per kilogram per day. The big benefits were shown at the high, experimental end, not at the dietary trickle a mushroom provides.
• The cancer question is genuinely two-sided. Because tumors love antioxidants and can build extra OCTN1 doorways, there is a theoretical worry that loading up could help an existing cancer defend itself. But it cuts the other way too: preventing oxidative damage prevents some of the mutations that start cancers, and ergothioneine has been shown to kill colorectal-cancer cells outright by triggering a form of programmed cell death.^[39] The science is split, so the sensible posture is moderation plus a vet’s input if a rat actually has a tumor, not blanket avoidance and not blind loading.
• It is exceptionally safe, which is the easy part. Ergothioneine is approved as a novel food in the EU and is the subject of US FDA GRAS notices, with a rat no-adverse-effect level of eight hundred milligrams per kilogram per day and no genotoxicity or reproductive toxicity found.^[40] Even the high experimental doses sit more than tenfold under that ceiling. The safety case is strong; it is the benefit-in-your-rat case that is still open.
• It is a supplement, not a medicine. Ergothioneine does not kill the Mycoplasma that drives chronic respiratory disease, and it does not reverse established kidney failure. A rat with labored breathing, weight loss, or any sudden change needs a vet. No supplement replaces that.

The frame that makes all of this hang together is the taurine story. Cats cannot make enough taurine; when commercial food left it out, cats went blind and died of heart failure, until the deficiency was found and the food industry simply added it back, after which the disease became rare.^[41] Ergothioneine has the same shape: a diet-only compound the body works hard to keep, flagged as a “longevity vitamin” that modern processed diets under-supply,^[42] and almost entirely absent from the lab blocks and kibble we feed captive rats. Whether it turns out to be the taurine moment for rats is still an open question. It is a question worth asking, and keeping ergothioneine in the diet is a low-risk, plausibly high-value thing to do while the science fills in.

The open questions, and the tests that would settle them

The hypotheses in section 5 are only worth raising if someone can check them, so here is each one stated as a clean experiment: the single test that would confirm or kill it, what you would expect to see if it were true, and what would falsify it. A wrong prediction here is as useful as a right one. A few of these are ones our blonde Rab38 rats are uniquely placed to answer, marked below. If you run a lab and one of these is cheap to try, please do, and tell us what you find. These sit alongside the genetics, behaviour, and physiology questions on our open research questions hub.

Play Inner Space: The Sulfur Sentinel

Keep reading: The ergothioneine overview (the plain-language version and the practical “how to add it” guide) · Play Inner Space: The Sulfur Sentinel · Open the dosing calculator (EGT) · Roof rat health hub

We don’t sell ergothioneine, or anything else. No products, no affiliate links, no sponsors, no compensation of any kind. This page exists to raise awareness and help rats. Please do your own research and talk to a vet about what is right for yours.

References

• [1] Gründemann D et al. “Discovery of the ergothioneine transporter.” Proc Natl Acad Sci U S A 2005;102(14):5256-61. PubMed.
• [2] Fong ZW, Tang RMY, Cheah IK, Leow DMK, Chen L, Halliwell B. “Ergothioneine and mitochondria: An important protective mechanism?.” Biochemical and biophysical research communications 2024;726:150269. PubMed.
• [3] Akanmu D, Cecchini R, Aruoma OI, Halliwell B. “The antioxidant action of ergothioneine.” Archives of biochemistry and biophysics 1991;288(1):10-6. PubMed.
• [4] Kato Y, Kubo Y, Iwata D, et al. “Gene knockout and metabolome analysis of carnitine/organic cation transporter OCTN1.” Pharmaceutical Research 2010;27(5):832-840. PubMed.
• [5] Borodina I, Kenny LC, McCarthy CM, et al. “The biology of ergothioneine, an antioxidant nutraceutical.” Nutrition Research Reviews 2020;33(2):190-217. PubMed.
• [6] Nakamura T et al. “Functional characterization of ergothioneine transport by rat organic cation/carnitine transporter Octn1 (slc22a4).” Biological & Pharmaceutical Bulletin 2008;31(8):1580-1584. PubMed.
• [7] Urban TJ, Yang C, Lagpacan LL, et al. “Functional effects of protein sequence polymorphisms in the organic cation/ergothioneine transporter OCTN1 (SLC22A4).” Pharmacogenetics and Genomics 2007;17(9):773-782. PubMed.
• [8] Chen Y, Lu T, Pettersson-Kymmer U, et al. “Genomic atlas of the plasma metabolome prioritizes metabolites implicated in human diseases.” Nature Genetics 2023;55(1):44-53. PubMed.
• [9] Cheah IK, Tang RMY, Yew TSZ, Lim KHC, Halliwell B. “Administration of Pure Ergothioneine to Healthy Human Subjects: Uptake, Metabolism, and Effects on Biomarkers of Oxidative Damage and Inflammation.” Antioxidants & Redox Signaling 2017;26(5):193-206. PubMed.
• [10] Yamashita Y, Yamashita M. “Identification of a novel selenium-containing compound, selenoneine, as the predominant chemical form of organic selenium in the blood of bluefin tuna.” Journal of Biological Chemistry 2010;285(24):18134-18138. PubMed.
• [11] Hseu YC, Lo HW, Korivi M, et al. “Dermato-protective properties of ergothioneine through induction of Nrf2/ARE-mediated antioxidant genes in UVA-irradiated human keratinocytes.” Free Radical Biology and Medicine 2015;86:102-117. PubMed.
• [12] Hseu YC, Vudhya Gowrisankar Y, Chen XZ, et al. “The Antiaging Activity of Ergothioneine in UVA-Irradiated Human Dermal Fibroblasts via the Inhibition of the AP-1 Pathway and the Activation of Nrf2-Mediated Antioxidant Genes.” Oxidative Medicine and Cellular Longevity 2020;2020:2576823. PubMed.
• [13] Li RW, Yang C, Sit AS, et al. “Uptake and protective effects of ergothioneine in human endothelial cells.” Journal of Pharmacology and Experimental Therapeutics 2014;350(3):691-700. PubMed.
• [14] Salama SA, Abd-Allah GM, Mohamadin AM. “Ergothioneine mitigates cisplatin-evoked nephrotoxicity via targeting Nrf2, NF-kB, and apoptotic signaling and inhibiting gamma-glutamyl transpeptidase.” Life Sciences 2021;278:119572. PubMed.
• [15] Dare A, Channa ML, Nadar A. “L-ergothioneine and its combination with metformin attenuates renal dysfunction in type-2 diabetic rat model by activating Nrf2 antioxidant pathway.” Biomedicine & Pharmacotherapy 2021;141:111921. PubMed.
• [16] Jenny KA, Mose G, Haupt DJ, et al. “Oxidized Forms of Ergothioneine Are Substrates for Mammalian Thioredoxin Reductase.” Antioxidants (Basel) 2022;11(2):185. PubMed.
• [17] Cheah IK, Halliwell B. “Ergothioneine, recent developments.” Redox biology 2021;42:101868. PubMed.
• [18] Devadas S, Zaritskaya L, Rhee SG, Oberley L, Williams MS. “Discrete generation of superoxide and hydrogen peroxide by T cell receptor stimulation: selective regulation of mitogen-activated protein kinase activation and fas ligand expression.” The Journal of experimental medicine 2002;195(1):59-70. PubMed.
• [19] Petrovic D et al. “Ergothioneine improves healthspan of aged animals by enhancing cGPDH activity through CSE-dependent persulfidation.” Cell Metabolism 2025;37(2):542-556.e14. PubMed.
• [20] Peng J et al. “Proteomic analysis reveals the potential mechanism of ergothioneine in preventing acute kidney injury to chronic kidney disease transition.” Archives of Biochemistry and Biophysics 2025;772:110534. PubMed.
• [21] Shinozaki Y, Furuichi K, et al. “Impairment of the carnitine/organic cation transporter 1-ergothioneine axis is mediated by intestinal transporter dysfunction in chronic kidney disease.” Kidney International 2017;92(6). PubMed.
• [22] Nakamichi N, Nakayama K, Ishimoto T, et al. “Food-derived hydrophilic antioxidant ergothioneine is distributed to the brain and exerts antidepressant effect in mice.” Brain and Behavior 2016;6(6):e00477. PubMed.
• [23] Shibagaki F, Ishimoto T, Kato Y, et al. “Ergothioneine Suppresses Amyloid beta-Induced Tau Phosphorylation and Cytotoxicity by Inactivating Glycogen Synthase Kinase-3beta in Cultured Neurons.” Current Molecular Pharmacology 2024;17(1):e18761429387340. PubMed.
• [24] Repine JE, Elkins ND. “Effect of ergothioneine on acute lung injury and inflammation in cytokine insufflated rats.” Preventive medicine 2012;54 Suppl(Suppl):S79-82. PubMed.
• [25] MANN T, LEONE E. “Studies on the metabolism of semen. VIII. Ergothioneine as a normal constituent of boar seminal plasma; purification and crystallization; site of formation and function.” The Biochemical journal 1953;53(1):140-8. PubMed.
• [26] Guo Q, Liu X, Li Y, et al. “Ergothioneine Improves the Quality of Boar Sperm During In Vitro Liquid Preservation by Regulating Mitochondrial Respiratory Chain.” Animals : an open access journal from MDPI 2025;15(10). PubMed.
• [27] Nagahara M, Namula Z, Lin Q, et al. “Effects of ergothioneine supplementation on meiotic competence and porcine oocyte development.” Veterinary world 2024;17(8):1748-1752. PubMed.
• [28] Chen Q, Zhou R, Yang C, et al. “Ergothioneine attenuates varicocele-induced testicular damage by upregulating HSP90AA1 in rats.” Journal of biochemical and molecular toxicology 2023;37(4):e23301. PubMed.
• [29] Wu X, George RL, Huang W, et al. “Structural and functional characteristics and tissue distribution pattern of rat OCTN1, an organic cation transporter, cloned from placenta.” Biochimica et biophysica acta 2000;1466(1-2):315-27. PubMed.
• [30] Forster R, Spézia F, Papineau D, et al. “Reproductive safety evaluation of L-Ergothioneine.” Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 2015;80:85-91. PubMed.
• [31] Oiso N et al. “The rat Ruby (R) locus is Rab38: identical mutations in Fawn-hooded and Tester-Moriyama rats derived from an ancestral Long Evans rat sub-strain.” Mammalian Genome 2004;15(4):307-314. PubMed.
• [32] Kido M, Tanaka K, Kimura G, Kuramoto T. “A fawn coat-colour mutant found in captive roof rats (Rattus rattus) carries a deletion in the Rab38 gene [conference presentation, in Japanese; original title 飼育クマネズミに見出された淡毛色変異体はRab38遺伝子に欠失を持つ].” 95th Annual Meeting of the Zoological Society of Japan, Nagasaki; presentation 1A0900 (Mammals/Genetics session), Tokyo University of Agriculture 2024. source.
• [33] Rangel-Filho A et al. “Rab38 modulates proteinuria in model of hypertension-associated renal disease.” Journal of the American Society of Nephrology 2013;24(2):283-292. PubMed.
• [34] Nielsen R, Christensen EI, Birn H. “Megalin and cubilin in proximal tubule protein reabsorption: from experimental models to human disease.” Kidney International 2016;89(1):58-67. PubMed.
• [35] Chen M, Yi Y, et al. “Metformin inhibits OCTN1- and OCTN2-mediated hepatic accumulation of doxorubicin and alleviates its hepatotoxicity in mice.” Toxicology 2024. PubMed.
• [36] Tschirka J, Kreisor M, Betz J, Gründemann D. “Substrate Selectivity Check of the Ergothioneine Transporter.” Drug Metabolism and Disposition 2018;46(6):779-785. PubMed.
• [37] Smith E et al. “Ergothioneine is associated with reduced mortality and decreased risk of cardiovascular disease.” Heart 2020;106(9):691-697. PubMed.
• [38] Katsube M et al. “Ergothioneine promotes longevity and healthy aging in male mice.” GeroScience 2024;46:3889-3909. PubMed.
• [39] D’Onofrio N, Martino E, Balestrieri A, et al. “Diet-derived ergothioneine induces necroptosis in colorectal cancer cells by activating the SIRT3/MLKL pathway.” FEBS Letters 2022;596(10):1313-1329. PubMed.
• [40] EFSA NDA Panel. “Safety of synthetic l-ergothioneine (Ergoneine) as a novel food pursuant to Regulation (EC) No 258/97.” EFSA Journal 2016;14(11):4629. DOI.
• [41] Pion PD et al. “Myocardial failure in cats associated with low plasma taurine: a reversible cardiomyopathy.” Science 1987;237:764-768. PubMed.
• [42] Beelman RB et al. “Is ergothioneine a longevity vitamin limited in the American diet?.” Journal of Nutritional Science 2020;9:e52. PubMed.
• [43] Reiter CP. “Association of genetic OCTN1/2 variants with tooth loss, cardiovascular risk factors and mortality (doctoral dissertation, Univ. Greifswald, 2025; SHIP-TREND cohort).” link.
• [44] Zivanovic J et al. “Selective Persulfide Detection Reveals Evolutionarily Conserved Antiaging Effects of S-Sulfhydration.” Cell Metab 2019;30(6):1152-1170. PubMed.
• [45] Petrovic D et al. “The Role of Protein Persulfidation in Brain Aging and Neurodegeneration.” Front Aging Neurosci 2021;13:674135. PubMed.
• [46] Williams ME et al. “Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy.” Am J Nephrol 2007;27(6):605-614. PubMed.
• [47] Alkhalaf A et al. “Effect of benfotiamine on advanced glycation endproducts and markers of endothelial dysfunction and inflammation in diabetic nephropathy.” PLoS One 2012;7(7):e40427. PubMed.
• [48] Camacho-Pereira J et al. “CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism.” Cell Metab 2016;23(6):1127-1139. PubMed.
• [49] Zhang L et al. “Rab38 targets to lamellar bodies and normalizes their sizes in lung alveolar type II epithelial cells.” American Journal of Physiology. Lung Cellular and Molecular Physiology 2011;301:L461-L477. PubMed.
• [50] Osanai K et al. “Exogenous gene transfer of Rab38 small GTPase ameliorates aberrant lung surfactant homeostasis in Ruby rats.” Respiratory Research 2017;18:70. PubMed.
• [51] Ninkovic I et al. “The role of Rab38 in platelet dense granule defects.” Journal of Thrombosis and Haemostasis 2008;6(12):2143-2151. PubMed.
• [52] Qureshi AA, Karpen CW, Qureshi N, et al. “Tocotrienols-induced inhibition of platelet thrombus formation and platelet aggregation in stenosed canine coronary arteries.” Lipids in health and disease 2011;10:58. PubMed.
• [53] Formukong EA, Evans AT, Evans FJ. “The inhibitory effects of cannabinoids, the active constituents of Cannabis sativa L. on human and rabbit platelet aggregation.” The Journal of pharmacy and pharmacology 1989;41(10):705-9. PubMed.